Plain-English translation of NCT03316261 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
The Freder1k Study is looking for newborns and very young infants who carry genetic markers that put them at higher risk for developing type 1 diabetes. By identifying these babies early—before any symptoms appear—researchers hope to enroll them in future studies that may prevent the disease from developing. Type 1 diabetes is a condition where the body's immune system attacks insulin-producing cells, and catching it early could change a child's health trajectory.
Type 1 diabetes is becoming more common in children and often comes as a sudden diagnosis. But scientists now know that a silent, asymptomatic phase happens first, during which the immune system is already attacking the pancreas. This trial exists to find babies in that early window so they can participate in studies testing whether early intervention can prevent type 1 diabetes from ever developing.
You likely qualify if…
You likely don't qualify if…
Participation involves a simple blood test or genetic screening of your infant to check for diabetes risk markers. If your baby is found to be at increased risk, you will be offered the opportunity to enroll them in future prevention trials. The initial screening itself is brief and non-invasive, though continued participation in any follow-up prevention studies would be discussed with you separately.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany
Enrollment target
~1,000,000 participants
Started
October 2017
Primary completion
August 2027
Age range
1 Day – 6 Weeks
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Anette-Gabriele Ziegler
Helmholtz Zentrum München, IDF-1
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.